Technical Data
Interferon gamma, Recombinant, Human (IFNg)
Growth Factors, Cytokines Storage: -20CShipping: Blue Ice
Interferon-gamma (IFN-g) is a lymphoid factor which possesses potent anti-viral activity. It has also been shown to stimulate macrophages and NK cells. Human IFN-g is a 16.7kD protein. Interferon gamma is the only known type II interferon. Under physiological conditions, interferon gamma is induced when T-lymphocytes, previously sensitized to an antigen, are exposed to the same antigen, hence its other name: immune interferon. IFNg is produced by lymphocytes expressing the surface antigens CD4 and CD8. The synthesis of IFN-gamma is induced, among other things, by Interleukin-2 , FGF-basic and EGF. Interferon gamma has demonstrated significant anti-proliferative effects in in vivo studies; however, its therapeutic effects have been limited. Endogenous IFN-g has been shown to be required for the protection of mice against mycobacteri and leishmaniasis. In the U.S., human IFN-g has been approved for reducing the frequency and severity of infections in patients with chronic granulomatous disease.

Recombinant Human Interferon gamma produced in E. coli is a single, non-glycosylated, polypeptide chain containing 144 amino acids and having a molecular mass of 16.879kD.

Biological Activity:
Biological Activity:
IFNg is fully biologically active when compared to standard. The specific activity as determined in a viral resistance assay is <0.05ng/ml, corresponding to a specific activity of 2.0x10e7 IU/mg.

Protein Content:
Protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280nm using the absorbency value of 0.640 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics).
2. Analysis by RP-HPLC, using a standard solution of IFN-gamma as a Reference Standard.

Amino Acid Sequence:

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O, 0.1% HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 6 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
Source: E. coli
Purity: >95% by RP-HPLC and SDS-PAGE. Chromatographically purified.
Form: Supplied as a lyophilized powder in 10mM sodium phosphate buffer, pH 7.4. Reconstitute in sterile dH2O, 0.1% HSA or BSA to a concentration 0.1mg/ml. Can be further diluted to other aqueous solutions.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Rubinstein, S., Familletti, P.C., Pestka, S.: Convenient Assay for Interferons. J. Virol. 37: 755-758 (1981). 2. Familletti, P. C., Rubinstein, S., Pestka, S.: A Convenient and Rapid Cytopathic Effect Inhibition Assay for Interferon. Methods in Enzymology 78: 387-394 (1981).
3. Discrimination of Acute Graft-versus-Host Disease from Infections by Enumeration of Peripheral Blood Interferon-gamma Spot-Forming Cells. Transplantation 2006 Feb 27;81(4):632-635
4. Determination of the Functional Status of Alloreactive T Cells by Interferon-gamma Kinetics. Transplantation 2006 Feb 27;81(4):590-8
5. Human Allograft Arterial Injury Is Ameliorated by Sirolimus and Cyclosporine and Correlates with Suppression of Interferon-gamma. Transplantation 2006 Feb 27;81(4):559-566
6. Astragaloside IV Exerts Antiviral Effects Against Coxsackievirus B3 by Upregulating Interferon-gamma. J Cardiovasc Pharmacol 2006 Feb;47(2):190-195
7. Role of interferon-gamma gene polymorphisms in susceptibility to IgA nephropathy: a family-based association study. Eur J Hum Genet 2006 Feb 22;

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.